Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome

Gut Microbes

Volumn 7, Issue 5, 2016, Pages 397-413

  Zeber Lubecka, Natalia ^a   Kulecka, Maria ^a   Ambrozkiewicz, Filip ^a   Paziewska, Agnieszka ^a   Goryca, Krzysztof ^b   Karczmarski, Jakub ^b   Rubel, Tymon ^c   Wojtowicz, Wojciech ^d   Mlynarz, Piotr ^d   Marczak, Lukasz ^e   Tomecki, Roman ^a   Mikula, Michal ^b   Ostrowski, Jerzy ^a,b  

^a MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c WARSAW UNIVERSITY OF TECHNOLOGY   (Poland)

^d WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^e INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

16s rRNA sequencing; irritable bowel syndrome; metabolomics; metagenomics; rifaximin

Indexed keywords

RIFAXIMIN; RNA 16S; RIFAMYCIN;

ACTINOBACTERIA; ADULT; ARTICLE; BACTEROIDETES; BIODIVERSITY; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; FECES ANALYSIS; FECES MICROFLORA; FEMALE; FIRMICUTES; GENE SEQUENCE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOME; OXIDATIVE PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEOBACTERIA; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; QUESTIONNAIRE; BACTERIUM; CLASSIFICATION; DRUG EFFECTS; FECES; GENETICS; INTESTINE; IRRITABLE BOWEL SYNDROME; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; TIME FACTOR; YOUNG ADULT;

ADULT; BACTERIA; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; MALE; METABOLOME; MIDDLE AGED; RIFAMYCINS; TIME FACTORS; YOUNG ADULT;

EID: 84981710144     PISSN: 19490976     EISSN: 19490984     Source Type: Journal    
DOI: 10.1080/19490976.2016.1215805     Document Type: Article

References (88)

1. A.S.Neish. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136:65-80; PMID:19026645; http://dx.doi.org/10.1053/j.gastro.2008.10.080
2. K.E.Fujimura, N.A.Slusher, M.D.Cabana, S.V.Lynch. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 2010; 8:435-54; PMID:20377338; http://dx.doi.org/10.1586/eri.10.14
3. N.P.Hyland, E.M.Quigley, E.Brint. Microbiota-host interactions in irritable bowel syndrome:epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol 2014; 20:8859-66; PMID:25083059
4. R.Cuomo, P.Andreozzi, F.P.Zito, V.Passananti, G.De Carlo, G.Sarnelli. Irritable bowel syndrome and food interaction. World J Gastroenterol 2014; 20:8837-45; PMID:25083057
5. A.C.Ford, E.M.Quigley M, B.E.Lacy, A.J.Lembo, Y.A.Saito, L.R.Schiller, E.E.Soffer, B.M.Spiegel, P.Moayyedi. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation:systematic review and meta-analysis. Am J Gastroenterol 2014; 109:1547-61, 1562; http://dx.doi.org/10.1038/ajg.2014.202
6. D.A.Drossman. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006; 130:1377-90; PMID:16678553; http://dx.doi.org/10.1053/j.gastro.2006.03.008
7. K.N.Lee, O.Y.Lee. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol 2014; 20:8886-97; PMID:25083061
8. D.A.Drossman, M.Camilleri, E.A.Mayer, W.E.Whitehead. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123:2108-31; PMID:12454866; http://dx.doi.org/10.1053/gast.2002.37095
9. H.K.Bradley, G.M.Wyatt, C.E.Bayliss, J.O.Hunter. Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 1987; 23:29-32; PMID:3820268; http://dx.doi.org/10.1099/00222615-23-1-29
10. J.M.Si, Y.C.Yu, Y.J.Fan, S.J.Chen. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10:1802-5; PMID:15188510; http://dx.doi.org/10.3748/wjg.v10.i12.1802
11. E.Malinen, T.Rinttilä, K.Kajander, J.Mättö, A.Kassinen, L.Krogius, M.Saarela, R.Korpela, A.Palva. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100:373-82; PMID:15667495; http://dx.doi.org/10.1111/j.1572-0241.2005.40312.x
12. A.Lyra, T.Rinttilä, J.Nikkilä, L.Krogius-Kurikka, K.Kajander, E.Malinen, J.Mättö, L.Mäkelä, A.Palva. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009; 15:5936-45; PMID:20014457; http://dx.doi.org/10.3748/wjg.15.5936
13. C.Codling, L.O'Mahony, F.Shanahan, E.M.Quigley, J.R.Marchesi. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55:392-7; PMID:19693670; http://dx.doi.org/10.1007/s10620-009-0934-x
14. V.Taverniti, S.Guglielmetti. Methodological issues in the study of intestinal microbiota in irritable bowel syndrome. World J Gastroenterol 2014; 20:8821-36; PMID:25083056
15. J.Mättö, L.Maunuksela, K.Kajander, A.Palva, R.Korpela, A.Kassinen, M.Saarela. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome–a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43:213-22; http://dx.doi.org/10.1016/j.femsim.2004.08.009
16. A.Kassinen, L.Krogius-Kurikka, H.Mäkivuokko, T.Rinttilä, L.Paulin, J.Corander, E.Malinen, J.Apajalahti, A.Palva. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterol 2007; 133:24-33; PMID:17631127; http://dx.doi.org/10.1053/j.gastro.2007.04.005
17. L.Cuoco, M.Salvagnini. Small intestine bacterial overgrowth in irritable bowel syndrome:a retrospective study with rifaximin. Minerva Gastroenterol Dietol 2006; 52:89-95; PMID:16554709
18. S.Peralta, C.Cottone, T.Doveri, P.L.Almasio, A.Craxi. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms:experience with Rifaximin. World J Gastroenterol 2009; 15:2628-31; PMID:19496193; http://dx.doi.org/10.3748/wjg.15.2628
19. J.Yang, H.R.Lee, K.Low, S.Chatterjee, M.Pimentel. Rifaximin vs. other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008; 53:169-74; PMID:17520365; http://dx.doi.org/10.1007/s10620-007-9839-8
20. E.C.Lauritano, M.Gabrielli, A.Lupascu, A.Santoliquido, G.Nucera, E.Scarpellini, F.Vincenti, G.Cammarota, R.Flore, P.Pola, et al. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 22:31-5; PMID:15963077; http://dx.doi.org/10.1111/j.1365-2036.2005.02516.x
21. E.C.Lauritano, M.Gabrielli, E.Scarpellini, V.Ojetti, D.Roccarina, A.Villita, E.Fiore, R.Flore, A.Santoliquido, P.Tondi, et al. Antibiotic therapy in small intestinal bacterial overgrowth:rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci 2009; 13:111-6; PMID:19499846
22. E.Scarpellini, M.Gabrielli, C.E.Lauritano, A.Lupascu, G.Merra, G.Cammarota, I.A.Cazzato, G.Gasbarrini, A.Gasbarrini. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2007; 25:781-6; PMID:17373916; http://dx.doi.org/10.1111/j.1365-2036.2007.03259.x
23. M.Pimentel, A.Lembo, W.D.Chey, S.Zakko, Y.Ringel, J.Yu, S.M.Mareya, A.L.Shaw, E.Bortey, W.P.Forbes, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22-32; PMID:21208106; http://dx.doi.org/10.1056/NEJMoa1004409
24. E.Scarpellini, V.Giorgio, M.Gabrielli, S.Filoni, G.Vitale, A.Tortora, V.Ojetti, G.Gigante, C.Fundar∫, A.Gasbarrini. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17:1314-20; PMID:23740443
25. S.B.Menees, M.Maneerattannaporn, H.M.Kim, W.D.Chey. The efficacy and safety of rifaximin for the irritable bowel syndrome:a systematic review and meta-analysis. Am J Gastroenterol 2012; 107:28-35; quiz 36; PMID:22045120; http://dx.doi.org/10.1038/ajg.2011.355
26. M.Di Stefano, A.Strocchi, S.Malservisi, G.Veneto, A.Ferrieri, G.R.Corazza. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000; 14:1001-8; PMID:10930893; http://dx.doi.org/10.1046/j.1365-2036.2000.00808.x
27. A.Rezaie, S.Nikfar, M.Abdollahi. The place of antibiotics in management of irritable bowel syndrome:a systematic review and meta-analysis. Arch Med Sci 2010; 6:49-55; PMID:22371720; http://dx.doi.org/10.5114/aoms.2010.13507
28. M.Pimentel. Review article:potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 2016; 43 Suppl 1:37-49; PMID:26618924; http://dx.doi.org/10.1111/apt.13437
29. N.Iorio, Z.Malik, R.Schey. Profile of rifaximin and its potential in the treatment of irritable bowel syndrome. Clin Exp Gastroenterol 2015; 8:159-67; PMID:26089696
30. P.Meyrat, E.Safroneeva, A.M.Schoepfer. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012; 36:1084-93; PMID:23066911; http://dx.doi.org/10.1111/apt.12087
31. M.Pimentel, S.Park, J.Mirocha, S.V.Kane, Y.Kong. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome:a randomized trial. Ann Intern Med 2006; 145:557-63; PMID:17043337; http://dx.doi.org/10.7326/0003-4819-145-8-200610170-00004
32. A.I.Sharara, E.Aoun, H.Abdul-Baki, R.Mounzer, S.Sidani, I.Elhajj. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101:326-33; PMID:16454838; http://dx.doi.org/10.1111/j.1572-0241.2006.00458.x
33. I.B.Jeffery, P.W.O'Toole, L.Öhman, M.J.Claesson, J.Deane, E.M.Quigley, M.Simrén. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61:997-1006; PMID:22180058; http://dx.doi.org/10.1136/gutjnl-2011-301501
34. S.Soldi, S.Vasileiadis, F.Uggeri, M.Campanale, L.Morelli, M.V.Fogli, F.Calanni, M.Grimaldi, A.Gasbarrini. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients:a molecular approach. Clin Exp Gastroenterol 2015; 8:309-25; PMID:26673000; http://dx.doi.org/10.2147/CEG.S89999
35. R.L.Soares. Irritable bowel syndrome:a clinical review. World J Gastroenterol 2014; 20:12144-60; PMID:25232249; http://dx.doi.org/10.3748/wjg.v20.i34.12144
36. M.Bellini, D.Gambaccini, C.Stasi, M.T.Urbano, S.Marchi, P.Usai-Satta. Irritable bowel syndrome:a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol 2014; 20:8807-20; PMID:25083055
37. D.Xu, J.Gao, M.Gillilland, X.Wu, I.Song, J.Y.Kao, C.Owyang. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterol 2014; 146:484-496. e4; PMID:24161699; http://dx.doi.org/10.1053/j.gastro.2013.10.026
38. G.Le Gall, S.O.Noor, K.Ridgway, L.Scovell, C.Jamieson, I.T.Johnson, I.J.Colquhoun, E.K.Kemsley, A.Narbad. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res 2011; 10:4208-18; PMID:21761941; http://dx.doi.org/10.1021/pr2003598
39. M.H.van Nuenen, R.A.de Ligt, R.P.Doornbos, J.C.van der Woude, E.J.Kuipers, K.Venema. The influence of microbial metabolites on human intestinal epithelial cells and macrophages in vitro. FEMS Immunol Med Microbiol 2005; 45:183-9; PMID:15939578; http://dx.doi.org/10.1016/j.femsim.2005.03.010
40. V.De Preter, K.Verbeke. Metabolomics as a diagnostic tool in gastroenterology. World J Gastrointest Pharmacol Ther 2013; 4:97-107; PMID:24199025
41. K.Kajander, E.Myllyluoma, S.Kyrönpalo, M.Rasmussen, P.Sipponen, I.Mattila, T.Seppänen-Laakso, H.Vapaatalo, M.Oresic, R.Korpela. Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome. World J Gastroenterol 2009; 15:6068-74; PMID:20027679; http://dx.doi.org/10.3748/wjg.15.6068
42. I.Ahmed, R.Greenwood, L.Costello Bde, N.M.Ratcliffe, C.S.Probert. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS One 2013; 8:e58204.
43. K.Ponnusamy, J.N.Choi, J.Kim, S.Y.Lee, C.H.Lee. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 2011; 60:817-27; PMID:21330412; http://dx.doi.org/10.1099/jmm.0.028126-0
44. N.Zeber-Lubecka, M.Kulecka, F.Ambrozkiewicz, A.Paziewska, M.Lechowicz, E.Konopka, U.Majewska, M.Borszewska-Kornacka, M.Mikula, B.Cukrowska, et al. Effect of Saccharomyces boulardii and Mode of Delivery on the Early Development of the Gut Microbial Community in Preterm Infants. PLoS One 2016; 11:e0150306; PMID:26918330; http://dx.doi.org/10.1371/journal.pone.0150306
45. P.D.Schloss, S.L.Westcott, T.Ryabin, J.R.Hall, M.Hartmann, E.B.Hollister, R.A.Lesniewski, B.B.Oakley, D.H.Parks, C.J.Robinson, et al. Introducing mothur:open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009; 75:7537-41; PMID:19801464; http://dx.doi.org/10.1128/AEM.01541-09
46. C.Manichanh, N.Borruel, F.Casellas, F.Guarner. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 2012; 9:599-608; PMID:22907164; http://dx.doi.org/10.1038/nrgastro.2012.152
47. X.C.Morgan, N.Segata, C.Huttenhower. Biodiversity and functional genomics in the human microbiome. Trends Genet 2013; 29:51-8; PMID:23140990; http://dx.doi.org/10.1016/j.tig.2012.09.005
48. M.Arumugam, J.Raes, E.Pelletier, D.Le Paslier, T.Yamada, D.R.Mende, G.R.Fernandes, J.Tap, T.Bruls, J.M.Batto, et al. Enterotypes of the human gut microbiome. Nature 2011; 473:174-80; PMID:21508958; http://dx.doi.org/10.1038/nature09944
49. S.E.Power, P.W.O'Toole, C.Stanton, R.P.Ross, G.F.Fitzgerald. Intestinal microbiota, diet and health. Br J Nutr 2014; 111:387-402; PMID:23931069; http://dx.doi.org/10.1017/S0007114513002560
50. S.Ghorbani, A.Nejad, D.Law, K.S.Chua, M.M.Amichai, M.Pimentel. Healthy control subjects are poorly defined in case-control studies of irritable bowel syndrome. Ann Gastroenterol 2015; 28:87-93; PMID:25609236
51. S.J.Salipante, T.Kawashima, C.Rosenthal, D.R.Hoogestraat, L.A.Cummings, D.J.Sengupta, T.T.Harkins, B.T.Cookson, N.G.Hoffman. Performance comparison of Illumina and ion torrent next-generation sequencing platforms for 16S rRNA-based bacterial community profiling. Appl Environ Microbiol 2014; 80:7583-91; PMID:25261520; http://dx.doi.org/10.1128/AEM.02206-14
52. A.W.Walker, J.C.Martin, P.Scott, J.Parkhill, H.J.Flint, K.P.Scott. 16S rRNA gene-based profiling of the human infant gut microbiota is strongly influenced by sample processing and PCR primer choice. Microbiome 2015; 3:26; PMID:26120470; http://dx.doi.org/10.1186/s40168-015-0087-4
53. M.Rajilić-Stojanović, H.Smidt, W.M.de Vos. Diversity of the human gastrointestinal tract microbiota revisited. Environ Microbiol 2007; 9:2125-36; PMID:17686012; http://dx.doi.org/10.1111/j.1462-2920.2007.01369.x
54. L.Krogius-Kurikka, A.Lyra, E.Malinen, J.Aarnikunnas, J.Tuimala, L.Paulin, H.Mäkivuokko, K.Kajander, A.Palva. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9:95; PMID:20015409; http://dx.doi.org/10.1186/1471-230X-9-95
55. I.M.Carroll, T.Ringel-Kulka, J.P.Siddle, Y.Ringel. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24:521-30, e248; PMID:22339879; http://dx.doi.org/10.1111/j.1365-2982.2012.01891.x
56. P.Enck, K.Zimmermann, K.Rusch, A.Schwiertz, S.Klosterhalfen, J.-S.Frick. The effects of ageing on the colonic bacterial microflora in adults. Z Gastroenterol 2009; 47:653-8; PMID:19606407; http://dx.doi.org/10.1055/s-0028-1109055
57. C.Chassard, M.Dapoigny, K.P.Scott, L.Crouzet, C.Del'homme, P.Marquet, J.C.Martin, G.Pickering, D.Ardid, A.Eschalier, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35:828-38; PMID:22315951; http://dx.doi.org/10.1111/j.1365-2036.2012.05007.x
58. I.M.Carroll, Y.H.Chang, J.Park, R.B.Sartor, Y.Ringel. Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Gut Pathog 2010; 2:19; PMID:21143915; http://dx.doi.org/10.1186/1757-4749-2-19
59. M.R.Sheikh Sajjadieh, L.V.Kuznetsova, V.B.Bojenko. Dysbiosis in ukrainian children with irritable bowel syndrome affected by natural radiation. Iran J Pediatr 2012; 22:364-8; PMID:23400266
60. C.Tana, Y.Umesaki, A.Imaoka, T.Handa, M.Kanazawa, S.Fukudo. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22:512-9, e114-115; PMID:19903265
61. P.B.Eckburg, E.M.Bik, C.N.Bernstein, E.Purdom, L.Dethlefsen, M.Sargent, S.R.Gill, K.E.Nelson, D.A.Relman. Diversity of the human intestinal microbial flora. Science 2005; 308:1635-8; PMID:15831718; http://dx.doi.org/10.1126/science.1110591
62. A.P.Kerckhoffs, K.Ben-Amor, M.Samsom, M.E.van der Rest, J.de Vogel, J.Knol, L.M.Akkermans. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol 2011; 60:236-45; PMID:20947663; http://dx.doi.org/10.1099/jmm.0.022848-0
63. D.M.Saulnier, K.Riehle, T.A.Mistretta, M.A.Diaz, D.Mandal, S.Raza, E.M.Weidler, X.Qin, C.Coarfa, A.Milosavljevic, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. Gastroenterology 2011; 141:1782-91; PMID:21741921; http://dx.doi.org/10.1053/j.gastro.2011.06.072
64. L.Rigsbee, R.Agans, V.Shankar, H.Kenche, H.J.Khamis, S.Michail, O.Paliy. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2012; 107:1740-51; PMID:22986438; http://dx.doi.org/10.1038/ajg.2012.287
65. A.Durbán, J.J.Abellán, N.Jiménez-Hernández, P.Salgado, M.Ponce, J.Ponce, V.Garrigues, A.Latorre, A.Moya. Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome. Environ Microbiol Rep 2012; 4:242-7; http://dx.doi.org/10.1111/j.1758-2229.2012.00327.x
66. R.Spiller, K.Garsed. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136:1979-88; PMID:19457422; http://dx.doi.org/10.1053/j.gastro.2009.02.074
67. M.Pimentel, A.Lembo, W.D.Chey, S.Zakko, Y.Ringel, J.Yu, S.M.Mareya, A.L.Shaw, E.Bortey, W.P.Forbes, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22-32; PMID:21208106; http://dx.doi.org/10.1056/NEJMoa1004409
68. G.C.Wall, G.A.Bryant, M.M.Bottenberg, E.D.Maki, A.R.Miesner. Irritable bowel syndrome:a concise review of current treatment concepts. World J Gastroenterol 2014; 20:8796-806; PMID:25083054
69. P.Schoenfeld, M.Pimentel, L.Chang, A.Lembo, W.D.Chey, J.Yu, C.Paterson, E.Bortey, W.P.Forbes. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation:a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014; 39:1161-8; PMID:24697851; http://dx.doi.org/10.1111/apt.12735
70. M.Saadi, R.W.McCallum. Rifaximin in irritable bowel syndrome:rationale, evidence and clinical use. Ther Adv Chronic Dis 2013; 4:71-5; PMID:23556126; http://dx.doi.org/10.1177/2040622312472008
71. H.L.Koo, S.Sabounchi, D.B.Huang, H.L.DuPont. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012; 5:31-41; PMID:24833932; http://dx.doi.org/10.4137/CGast.S7382
72. C.L.Frissora, B.D.Cash. Review article:the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007; 25:1271-81; PMID:17509095; http://dx.doi.org/10.1111/j.1365-2036.2007.03313.x
73. J.S.Bajaj, D.M.Heuman, A.J.Sanyal, P.B.Hylemon, R.K.Sterling, R.T.Stravitz, M.Fuchs, J.M.Ridlon, K.Daita, P.Monteith, et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8:e60042; PMID:23565181; http://dx.doi.org/10.1371/journal.pone.0060042
74. G.Kakiyama, W.M.Pandak, P.M.Gillevet, P.B.Hylemon, D.M.Heuman, K.Daita, H.Takei, A.Muto, H.Nittono, J.M.Ridlon, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013; 58:949-55; PMID:23333527; http://dx.doi.org/10.1016/j.jhep.2013.01.003
75. D.Monleón, J.M.Morales, A.Barrasa, J.A.López, C.Vázquez, B.Celda. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed 2009; 22:342-8; http://dx.doi.org/10.1002/nbm.1345
76. M.Elia, M.B.Engfer, C.J.Green, D.B.Silk. Systematic review and meta-analysis:the clinical and physiological effects of fibre-containing enteral formulae. Aliment Pharmacol Ther 2008; 27:120-45; PMID:17922802; http://dx.doi.org/10.1111/j.1365-2036.2007.03544.x
77. L.Zumarraga, M.D.Levitt, F.Suarez. Absence of gaseous symptoms during ingestion of commercial fibre preparations. Aliment Pharmacol Ther 1997; 11:1067-72; PMID:9663831; http://dx.doi.org/10.1046/j.1365-2036.1997.00250.x
78. A.Dlugosz, B.Winckler, E.Lundin, K.Zakikhany, G.Sandström, W.Ye, L.Engstrand, G.Lindberg. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep 2015; 5:8508; PMID:25687743; http://dx.doi.org/10.1038/srep08508
79. G.F.Longstreth, W.G.Thompson, W.D.Chey, L.A.Houghton, F.Mearin, R.C.Spiller. Functional bowel disorders. Gastroenterology 2006; 130:1480-91; PMID:16678561; http://dx.doi.org/10.1053/j.gastro.2005.11.061
80. H.Li, B.Handsaker, A.Wysoker, T.Fennell, J.Ruan, N.Homer, G.Marth, G.Abecasis, R.Durbin, 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics 2009; 25:2078-9; PMID:19505943; http://dx.doi.org/10.1093/bioinformatics/btp352
81. FASTX-Toolkit [Internet]. [cited 2015 Apr 6]; Available from:http://hannonlab.cshl.edu/fastx_toolkit/index.html
82. D.H.Parks, G.W.Tyson, P.Hugenholtz, R.G.Beiko. STAMP:statistical analysis of taxonomic and functional profiles. Bioinformatics 2014; 30:3123-4; PMID:25061070; http://dx.doi.org/10.1093/bioinformatics/btu494
83. H.Wickham. ggplot2:Elegant Graphics for Data Analysis. 1st ed. 2009. Corr. 3rd printing 2010 edition. New York:Springer; 2010
84. Y.Benjamini, Y.Hochberg. Controlling the false discovery rate:A practical and powerful approach to multiple testing. J Royal Statistical Society Series B (Methodological) 1995; 57:289-300.
85. F.Faul, E.Erdfelder, A.-G.Lang, A.Buchner. G*Power 3:a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39:175-91; PMID:17695343; http://dx.doi.org/10.3758/BF03193146
86. M.G.Langille, J.Zaneveld, J.G.Caporaso, D.McDonald, D.Knights, J.A.Reyes, J.C.Clemente, D.E.Burkepile, R.L.Vega Thurber, R.Knight, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013; 31:814-21; PMID:23975157; http://dx.doi.org/10.1038/nbt.2676
87. T.Dawiskiba, S.Deja, A.Mulak, A.Ząbek, E.Jawień, D.Pawełka, M.Banasik, A.Mastalerz-Migas, W.Balcerzak, K.Kaliszewski, et al. Serum and urine metabolomic fingerprinting in diagnostics of inflammatory bowel diseases. World J Gastroenterol 2014; 20:163-74; PMID:24415869; http://dx.doi.org/10.3748/wjg.v20.i1.163
88. R.W.Kennard, L.A.Stone. Computer Aided Design of Experiments. Technometrics 1969; 11:137-48; http://dx.doi.org/10.1080/00401706.1969.10490666